{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:12:48Z","timestamp":1747195968025,"version":"3.40.4"},"reference-count":25,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,2,10]]},"abstract":"<jats:p>Highly active antiretroviral therapy (HAART) is associated with multiple metabolic disorders, including lipodystrophy, dyslipidaemia and insulin resistance. HIV\/HAART-associated lipodystrophy syndrome (HALS) is characterised by subcutaneous fat wasting, central fat accumulation and increased risk of diabetes. Thiazolidinediones are considered a promising treatment for HALS, because they improve insulin sensitivity and increase subcutaneous fat mass. In previous studies, pioglitazone increased overall fat mass in patients with HALS but whether fat distribution changes remains unclear. We describe a HALS patient with diabetes treated with pioglitazone. Prior to pioglitazone therapy, he had hollowed cheeks, loss of fat in the extremities and abdominal obesity. 18 months after starting pioglitazone and switching his HAART regimens, T1-weighted MRI showed obvious increases in the subcutaneous fat mass of the neck and upper trunk, but no changes in the cheeks and extremities. Pioglitazone therapy for HALS could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions.<\/jats:p>","DOI":"10.1136\/bcr-2015-213637","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T16:03:29Z","timestamp":1456416209000},"page":"bcr2015213637","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Pioglitazone therapy for HIV\/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions"],"prefix":"10.1136","volume":"2016","author":[{"given":"Sadanori","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,2,25]]},"reference":[{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.1.51"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1019"},{"issue":"(Suppl 1)","key":"2025042702484658000_2016.feb25_3.bcr2015213637.3","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.4103\/2230-8210.94250","article-title":"Pathogenesis and treatment of human immunodeficiency virus lipodystrophy","volume":"16","author":"Jain","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.4","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31819c291b"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.5","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-011-9565-z"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11705"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.7","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2002.137"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2004.07.008","article-title":"Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial","volume":"54","author":"Smith","year":"2005","journal-title":"Metab Clin Exp"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.9","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12512"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.10","first-page":"171","article-title":"Thiazolidinediones in the treatment of HIV\/HAART-associated lipodystrophy syndrome","volume":"15","author":"Edgeworth","year":"2013","journal-title":"AIDS Rev"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-183"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00978.x"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","article-title":"Rosiglitazone in the treatment of HAART-associated lipodystrophy\u2014a randomized double-blind placebo-controlled study","volume":"8","author":"Sutinen","year":"2003","journal-title":"Antivir Ther (Lond)"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-10-200405180-00008"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.15","first-page":"99","article-title":"Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART","volume":"14","author":"Tomazic","year":"2005","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.16","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000279706.24428.78"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.17","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2007.6.791"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1202779"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/QAD.0b013e328339e274","article-title":"Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens","volume":"24","author":"Tungsiripat","year":"2010","journal-title":"Aids"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15489-5"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/135965350801300107","article-title":"Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113)","volume":"13","author":"Slama","year":"2008","journal-title":"Antivir Ther (Lond)"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.22","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007070-00002"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.23","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200001070-00005"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.24","doi-asserted-by":"publisher","DOI":"10.1086\/655765"},{"key":"2025042702484658000_2016.feb25_3.bcr2015213637.25","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200404300-00011"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2015-213637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T09:48:54Z","timestamp":1745747334000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2015-213637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,25]]},"references-count":25,"alternative-id":["10.1136\/bcr-2015-213637"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2015-213637","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2016,2,25]]}}}